LivaNova PLC (NASDAQ:LIVN) Shares Acquired by UMB Bank n.a.

UMB Bank n.a. lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 340.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 837 shares of the company’s stock after purchasing an additional 647 shares during the period. UMB Bank n.a.’s holdings in LivaNova were worth $33,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in LIVN. Freestone Grove Partners LP acquired a new position in LivaNova in the fourth quarter valued at approximately $23,102,000. Artisan Partners Limited Partnership acquired a new stake in shares of LivaNova in the fourth quarter valued at $21,340,000. The Manufacturers Life Insurance Company increased its holdings in LivaNova by 163.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company’s stock valued at $25,303,000 after buying an additional 339,139 shares during the last quarter. AQR Capital Management LLC increased its holdings in LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock valued at $34,214,000 after buying an additional 328,313 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock worth $108,823,000 after purchasing an additional 265,291 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Trading Down 1.9%

Shares of LIVN opened at $45.76 on Monday. The stock’s fifty day simple moving average is $40.58 and its 200 day simple moving average is $43.80. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $57.35. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.50 billion, a P/E ratio of 108.95 and a beta of 0.90.

Analysts Set New Price Targets

A number of equities research analysts recently commented on LIVN shares. Robert W. Baird raised their price objective on shares of LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. Barclays reduced their price target on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a research report on Thursday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of LivaNova in a report on Tuesday, May 13th. Wolfe Research upgraded LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a research report on Tuesday, May 20th. Finally, Stifel Nicolaus reduced their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.